APS — Aptose Biosciences Income Statement
0.000.00%
Last trade - 00:00- CA$5.01m
- CA$19.60m
Annual income statement for Aptose Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 55.8 | 65.4 | 42.6 | 52.4 | 26.3 |
| Operating Profit | -55.8 | -65.4 | -42.6 | -52.4 | -26.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -55.2 | -65.4 | -41.8 | -51.2 | -25.4 |
| Net Income After Taxes | -55.2 | -65.4 | -41.8 | -51.2 | -25.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -55.2 | -65.4 | -41.8 | -51.2 | -25.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -55.2 | -65.4 | -41.8 | -51.2 | -25.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -304 | -330 | -204 | -227 | -36.3 |